BR112020001045A2 - proteínas sintéticas e usos terapêuticos das mesmas - Google Patents

proteínas sintéticas e usos terapêuticos das mesmas Download PDF

Info

Publication number
BR112020001045A2
BR112020001045A2 BR112020001045-6A BR112020001045A BR112020001045A2 BR 112020001045 A2 BR112020001045 A2 BR 112020001045A2 BR 112020001045 A BR112020001045 A BR 112020001045A BR 112020001045 A2 BR112020001045 A2 BR 112020001045A2
Authority
BR
Brazil
Prior art keywords
synthetic
fact
sequence
growth factor
linker
Prior art date
Application number
BR112020001045-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Erik D'hondt
Keith Alan Charlton
Original Assignee
In3Bio Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In3Bio Ltd. filed Critical In3Bio Ltd.
Publication of BR112020001045A2 publication Critical patent/BR112020001045A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR112020001045-6A 2017-07-18 2018-07-18 proteínas sintéticas e usos terapêuticos das mesmas BR112020001045A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533901P 2017-07-18 2017-07-18
US62/533,901 2017-07-18
PCT/IB2018/000898 WO2019016597A2 (en) 2017-07-18 2018-07-18 SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES

Publications (1)

Publication Number Publication Date
BR112020001045A2 true BR112020001045A2 (pt) 2020-09-08

Family

ID=63857968

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020001045-6A BR112020001045A2 (pt) 2017-07-18 2018-07-18 proteínas sintéticas e usos terapêuticos das mesmas

Country Status (12)

Country Link
US (1) US12134662B2 (https=)
EP (1) EP3655025A2 (https=)
JP (1) JP7751357B2 (https=)
KR (1) KR102903351B1 (https=)
CN (1) CN111246878A (https=)
AU (1) AU2018304957B2 (https=)
BR (1) BR112020001045A2 (https=)
CA (1) CA3070034A1 (https=)
IL (2) IL300235A (https=)
MX (1) MX2020000636A (https=)
RU (1) RU2020106669A (https=)
WO (1) WO2019016597A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112996534B (zh) 2018-08-07 2025-11-18 因斯瑞拜奥有限公司 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物
AU2020301638A1 (en) * 2019-06-25 2022-02-17 In3Bio Ltd. Stabilized chimeric synthetic proteins and therapeutic uses thereof
CN115379851A (zh) * 2019-11-07 2022-11-22 因斯瑞拜奥有限公司 使用生长因子抗体与非酪氨酸靶向激酶抑制剂的组合的方法和组合物
MX2024005177A (es) 2021-10-28 2024-08-27 In3Bio Ltd Métodos de uso de anticuerpos anti-fce para aumentar la actividad de los inhibidores de braf y kras.
USD1055117S1 (en) 2022-12-29 2024-12-24 Samsung Electronics Co., Ltd. Refrigerator

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US6645495B1 (en) 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
JP3855886B2 (ja) 2002-08-29 2006-12-13 トヨタ自動車株式会社 路面状態変化推定装置およびこれを搭載する自動車
JP4623625B2 (ja) * 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型５量体組換えワクチン
WO2007109673A2 (en) * 2006-03-20 2007-09-27 Stanford University Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
KR102274211B1 (ko) * 2011-11-23 2021-07-09 인3바이오 리미티드 재조합 단백질 및 그들의 치료적 용도
CN111978409B (zh) * 2013-03-15 2024-01-26 因斯瑞拜奥有限公司 自组装合成蛋白
US12595297B2 (en) * 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
FI3345613T3 (fi) * 2015-09-01 2023-07-28 Il Dong Pharma Koostumus käytettäväksi syövän tai angiogeneesiin liittyvän sairauden hoidossa käsittäen tuumoriin penetroituvan peptidin ja VEGF-estäjän fuusioproteiinin

Also Published As

Publication number Publication date
EP3655025A2 (en) 2020-05-27
JP7751357B2 (ja) 2025-10-08
WO2019016597A2 (en) 2019-01-24
AU2018304957A1 (en) 2020-02-13
JP2020527579A (ja) 2020-09-10
IL300235A (en) 2023-03-01
WO2019016597A3 (en) 2019-04-18
RU2020106669A (ru) 2021-08-18
IL272050B2 (en) 2023-07-01
RU2020106669A3 (https=) 2022-04-07
AU2018304957B2 (en) 2025-05-15
KR20200029010A (ko) 2020-03-17
KR102903351B1 (ko) 2025-12-24
IL272050B1 (en) 2023-03-01
US12134662B2 (en) 2024-11-05
CN111246878A (zh) 2020-06-05
US20210009716A1 (en) 2021-01-14
IL272050A (en) 2020-03-31
MX2020000636A (es) 2020-08-20
CA3070034A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
JP7470669B2 (ja) 組換えタンパク質及びそれらの治療的用途
BR112020001045A2 (pt) proteínas sintéticas e usos terapêuticos das mesmas
CN114269792B (zh) 稳定的嵌合合成蛋白及其治疗用途
HK1197890A (en) Recombinant proteins and their therapeutic uses
HK1197890B (en) Recombinant proteins and their therapeutic uses

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]